NDAINHALATIONSOLUTION
Approved
Jul 2009
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
TYVASO (treprostinil) by United Therapeutics is analogue. Approved for pulmonary arterial hypertension, pulmonary hypertension. First approved in 2009.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYVASO is an inhaled prostacycline analogue approved in 2009 for pulmonary arterial hypertension and pulmonary hypertension. It works by directly vasodilating pulmonary and systemic arterial beds while inhibiting platelet aggregation. The inhalation route offers a non-systemic alternative to parenteral prostacycline therapies.
Peak15.8 years to LOE
Product is in peak commercial phase with stable franchise; team is likely optimized for maintenance and line extension rather than new growth hires.
Mechanism of Action
analogue. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.
Pharmacologic Class:
Prostacycline Vasodilator
Indications (2)
Worked on TYVASO at United Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.